Category: Approval/Launch Region: Europe · United Kingdom Company: Astrazeneca Ltd

AstraZeneca, MSD Lynparza in combo with abiraterone recommends for marketing approval in EU to treat metastatic castration-resistant prostate cancer

AstraZeneca, MSD Lynparza in combo with abiraterone recommends for marketing approval in EU to treat metastatic castration-resistant prostate cancer
AstraZeneca and MSD

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!